178 related articles for article (PubMed ID: 19933973)
1. Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C Study.
Ryan J; Carrière I; Scali J; Dartigues JF; Tzourio C; Poncet M; Ritchie K; Ancelin ML
Neurology; 2009 Nov; 73(21):1729-37. PubMed ID: 19933973
[TBL] [Abstract][Full Text] [Related]
2. Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: the REMEMBER pilot study.
MacLennan AH; Henderson VW; Paine BJ; Mathias J; Ramsay EN; Ryan P; Stocks NP; Taylor AW
Menopause; 2006; 13(1):28-36. PubMed ID: 16607096
[TBL] [Abstract][Full Text] [Related]
3. Impact of a premature menopause on cognitive function in later life.
Ryan J; Scali J; Carrière I; Amieva H; Rouaud O; Berr C; Ritchie K; Ancelin ML
BJOG; 2014 Dec; 121(13):1729-39. PubMed ID: 24802975
[TBL] [Abstract][Full Text] [Related]
4. Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline.
Kang JH; Grodstein F
Neurobiol Aging; 2012 Jul; 33(7):1129-37. PubMed ID: 21122949
[TBL] [Abstract][Full Text] [Related]
5. Postmenopausal hormone therapy and risk of cognitive decline in community-dwelling aging women.
Kang JH; Weuve J; Grodstein F
Neurology; 2004 Jul; 63(1):101-7. PubMed ID: 15249618
[TBL] [Abstract][Full Text] [Related]
6. Life-time estrogen exposure and cognitive functioning in later life.
Ryan J; Carrière I; Scali J; Ritchie K; Ancelin ML
Psychoneuroendocrinology; 2009 Feb; 34(2):287-298. PubMed ID: 18947934
[TBL] [Abstract][Full Text] [Related]
7. Lipid lowering agents, cognitive decline, and dementia: the three-city study.
Ancelin ML; Carrière I; Barberger-Gateau P; Auriacombe S; Rouaud O; Fourlanos S; Berr C; Dupuy AM; Ritchie K
J Alzheimers Dis; 2012; 30(3):629-37. PubMed ID: 22451317
[TBL] [Abstract][Full Text] [Related]
8. Postmenopausal hormone therapy and risk of stroke: A pooled analysis of data from population-based cohort studies.
Carrasquilla GD; Frumento P; Berglund A; Borgfeldt C; Bottai M; Chiavenna C; Eliasson M; Engström G; Hallmans G; Jansson JH; Magnusson PK; Nilsson PM; Pedersen NL; Wolk A; Leander K
PLoS Med; 2017 Nov; 14(11):e1002445. PubMed ID: 29149179
[TBL] [Abstract][Full Text] [Related]
9. Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction.
Yaffe K; Haan M; Byers A; Tangen C; Kuller L
Neurology; 2000 May; 54(10):1949-54. PubMed ID: 10822435
[TBL] [Abstract][Full Text] [Related]
10. Postmenopausal hormone therapy and cognitive function in healthy older women.
Grodstein F; Chen J; Pollen DA; Albert MS; Wilson RS; Folstein MF; Evans DA; Stampfer MJ
J Am Geriatr Soc; 2000 Jul; 48(7):746-52. PubMed ID: 10894312
[TBL] [Abstract][Full Text] [Related]
11. Cerebrovascular disease, APOE epsilon4 allele and cognitive decline in a cognitively normal population.
Qiu C; Winblad B; Fratiglioni L
Neurol Res; 2006 Sep; 28(6):650-6. PubMed ID: 16945218
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E ε4 and later-life decline in cognitive function and grip strength.
Batterham PJ; Bunce D; Cherbuin N; Christensen H
Am J Geriatr Psychiatry; 2013 Oct; 21(10):1010-9. PubMed ID: 23567378
[TBL] [Abstract][Full Text] [Related]
13. Cognitive functions, apolipoprotein E genotype and hormonal replacement therapy of postmenopausal women.
Bojar I; Gujski M; Raczkiewicz D; Rothenberg KG
Neuro Endocrinol Lett; 2013; 34(7):635-42. PubMed ID: 24464001
[TBL] [Abstract][Full Text] [Related]
14. The relation between APOE status and neuropsychological memory test performance: an analysis of the Canadian Study of Health and Aging.
Klages J; Fisk JD
Brain Cogn; 2002 Jul; 49(2):201-4. PubMed ID: 15259389
[TBL] [Abstract][Full Text] [Related]
15. Association between apolipoprotein E epsilon4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia.
Jonker C; Schmand B; Lindeboom J; Havekes LM; Launer LJ
Arch Neurol; 1998 Aug; 55(8):1065-9. PubMed ID: 9708956
[TBL] [Abstract][Full Text] [Related]
16. Cognitive resilience among APOE ε4 carriers in the oldest old.
Hayden KM; Gaussoin SA; Hunter JC; Manson JE; Sachs BC; Shadyab AH; Tindle HA; Mossavar-Rahmani Y; Mozhui K; Snively BM; Rapp SR; Resnick SM
Int J Geriatr Psychiatry; 2019 Dec; 34(12):1833-1844. PubMed ID: 31418472
[TBL] [Abstract][Full Text] [Related]
17. APOE genotype, memory test performance, and the risk of Alzheimer's disease in the Canadian Study of Health and Aging.
Klages JD; Fisk JD; Rockwood K
Dement Geriatr Cogn Disord; 2003; 15(1):1-5. PubMed ID: 12457072
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal analysis of the effect of apolipoprotein E epsilon4 and education on cognitive performance in elderly subjects: the PAQUID study.
Winnock M; Letenneur L; Jacqmin-Gadda H; Dallongeville J; Amouyel P; Dartigues JF
J Neurol Neurosurg Psychiatry; 2002 Jun; 72(6):794-7. PubMed ID: 12023428
[TBL] [Abstract][Full Text] [Related]
19. Timing of hormone therapy and dementia: the critical window theory revisited.
Whitmer RA; Quesenberry CP; Zhou J; Yaffe K
Ann Neurol; 2011 Jan; 69(1):163-9. PubMed ID: 21280086
[TBL] [Abstract][Full Text] [Related]
20. Plasma levels of apolipoprotein E and cognitive function in old age.
Mooijaart SP; van Vliet P; van Heemst D; Rensen PC; Berbée JF; Jolles J; de Craen AJ; Westendorp RG
Ann N Y Acad Sci; 2007 Apr; 1100():148-61. PubMed ID: 17460173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
